Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project

H. Avet-Loiseau, B. G M Durie, M. Cavo, M. Attal, N. Gutierrez, J. Haessler, H. Goldschmidt, R. Hajek, J. H. Lee, O. Sezer, B. Barlogie, J. Crowley, Rafael Fonseca, N. Testoni, F. Ross, S Vincent Rajkumar, P. Sonneveld, J. Lahuerta, P. Moreau, G. Morgan

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma.

Original languageEnglish (US)
Pages (from-to)711-717
Number of pages7
JournalLeukemia
Volume27
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Fluorescence In Situ Hybridization
Cytogenetics
Chromosome Aberrations
Survival
Disease-Free Survival
Albumins
Databases
Serum
Therapeutics

Keywords

  • cytogenetics
  • myeloma
  • prognostic

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma : An International Myeloma Working Group collaborative project. / Avet-Loiseau, H.; Durie, B. G M; Cavo, M.; Attal, M.; Gutierrez, N.; Haessler, J.; Goldschmidt, H.; Hajek, R.; Lee, J. H.; Sezer, O.; Barlogie, B.; Crowley, J.; Fonseca, Rafael; Testoni, N.; Ross, F.; Rajkumar, S Vincent; Sonneveld, P.; Lahuerta, J.; Moreau, P.; Morgan, G.

In: Leukemia, Vol. 27, No. 3, 03.2013, p. 711-717.

Research output: Contribution to journalArticle

Avet-Loiseau, H, Durie, BGM, Cavo, M, Attal, M, Gutierrez, N, Haessler, J, Goldschmidt, H, Hajek, R, Lee, JH, Sezer, O, Barlogie, B, Crowley, J, Fonseca, R, Testoni, N, Ross, F, Rajkumar, SV, Sonneveld, P, Lahuerta, J, Moreau, P & Morgan, G 2013, 'Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project', Leukemia, vol. 27, no. 3, pp. 711-717. https://doi.org/10.1038/leu.2012.282
Avet-Loiseau, H. ; Durie, B. G M ; Cavo, M. ; Attal, M. ; Gutierrez, N. ; Haessler, J. ; Goldschmidt, H. ; Hajek, R. ; Lee, J. H. ; Sezer, O. ; Barlogie, B. ; Crowley, J. ; Fonseca, Rafael ; Testoni, N. ; Ross, F. ; Rajkumar, S Vincent ; Sonneveld, P. ; Lahuerta, J. ; Moreau, P. ; Morgan, G. / Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma : An International Myeloma Working Group collaborative project. In: Leukemia. 2013 ; Vol. 27, No. 3. pp. 711-717.
@article{4bad23a3f6414c2da59a7946c5a7f8c4,
title = "Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project",
abstract = "The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma.",
keywords = "cytogenetics, myeloma, prognostic",
author = "H. Avet-Loiseau and Durie, {B. G M} and M. Cavo and M. Attal and N. Gutierrez and J. Haessler and H. Goldschmidt and R. Hajek and Lee, {J. H.} and O. Sezer and B. Barlogie and J. Crowley and Rafael Fonseca and N. Testoni and F. Ross and Rajkumar, {S Vincent} and P. Sonneveld and J. Lahuerta and P. Moreau and G. Morgan",
year = "2013",
month = "3",
doi = "10.1038/leu.2012.282",
language = "English (US)",
volume = "27",
pages = "711--717",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma

T2 - An International Myeloma Working Group collaborative project

AU - Avet-Loiseau, H.

AU - Durie, B. G M

AU - Cavo, M.

AU - Attal, M.

AU - Gutierrez, N.

AU - Haessler, J.

AU - Goldschmidt, H.

AU - Hajek, R.

AU - Lee, J. H.

AU - Sezer, O.

AU - Barlogie, B.

AU - Crowley, J.

AU - Fonseca, Rafael

AU - Testoni, N.

AU - Ross, F.

AU - Rajkumar, S Vincent

AU - Sonneveld, P.

AU - Lahuerta, J.

AU - Moreau, P.

AU - Morgan, G.

PY - 2013/3

Y1 - 2013/3

N2 - The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma.

AB - The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma.

KW - cytogenetics

KW - myeloma

KW - prognostic

UR - http://www.scopus.com/inward/record.url?scp=84875209671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875209671&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.282

DO - 10.1038/leu.2012.282

M3 - Article

C2 - 23032723

AN - SCOPUS:84875209671

VL - 27

SP - 711

EP - 717

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -